Research findings last week included US vaccines maker Vaxcyte releasing highly impressive Phase III data for its VAX-31, for ...
A U.S. specialty biopharmaceutical company focused on dermatology, with operations centered on commercialization and late-stage development. The company is publicly listed on NYSE American under ...
A clinical-stage biopharmaceutical company with operational hubs in the United States and China. The company maintains offices in New Jersey and in multiple China locations (including Shanghai and ...
A clinical-stage biopharmaceutical company leveraging proprietary peptide technology to develop therapeutics for inflammation, hematology, and metabolic diseases, with multiple late-stage programs ...
US biopharma company Mineralys Therapeutics today announced the presentation of a new analysis from its pivotal Phase III ...
Given the impact of the illegal medicines trade on public health in Latin America, on confidence in the health system and on ...
US biotech Outlook Therapeutics, which is specializing in the development and commercialization of Lytenava (bevacizumab-vikg ...
Leading Swiss contract development and manufacturing organization (CDMO) Lonza and Onava, a US biotech building an AI-native ...
Israel-based Teva Pharmaceutical Industries US subsidiary today revealed that the US Food and Drug Administration (FDA) has ...
Data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 showed that Eli Lilly’s ...
India's pharmaceutical manufacturing industry is entering a delicate phase in its development. As uncertainty grows over its ...
Iambic Therapeutics, the San Diego-based AI drug discovery company, has set terms for a Nasdaq initial public offering of 9,375,000 shares priced at $15 to $17 each, under the proposed ticker IAM, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results